HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Last
$66.64
−$1.41 (−2.07%) 4:00 PM ET
Prev close $68.05
Open $67.95
Day high $68.80
Day low $66.44
Volume 1,565,300
Avg vol 1,472,097
Mkt cap
$8.06B
P/E ratio
25.93
FY Revenue
$1.40B
EPS
2.57
Gross Margin
83.62%
Sector
Healthcare
AI report sections
HALO
Halozyme Therapeutics, Inc.
Halozyme Therapeutics combines solid double-digit share price appreciation over the past year with bullish technical signals above key moving averages. The company’s high-margin, cash-generative business supports elevated returns on capital, while meaningful leverage and notable short interest introduce balance-sheet and sentiment-related risks. Valuation appears moderate relative to earnings and free cash flow but is rich versus book value and accompanied by a high debt-to-equity ratio.
AI summarized at 2:18 PM ET, 2026-02-03
AI summary scores
INTRADAY: 72 SWING: 78 LONG: 83
Volume vs average
Intraday (cumulative)
+58% (Above avg)
Vol/Avg: 1.58×
RSI
57.69 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
-0.01 (Weak)
MACD: -0.00 Signal: 0.01
Short-Term
+0.80 (Strong)
MACD: -0.02 Signal: -0.82
Long-Term
+0.63 (Strong)
MACD: -1.55 Signal: -2.18
Intraday trend score 70.60

Latest news

HALO No articles found.
News is temporarily unavailable.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal